Journal article
Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER
Abstract
PURPOSE: Post hoc analysis of the phase III HAWK and HARRIER studies to compare the reductions in subretinal hyper-reflective material (SHRM) thickness following brolucizumab 6 mg or aflibercept 2 mg treatment and to assess SHRM thickness and thickness variability as a potential biomarker of visual outcomes in patients with neovascular age-related macular degeneration (nAMD).
METHODS: Optical coherence tomography images from the brolucizumab …
Authors
Sadda S; Sarraf D; Khanani AM; Tadayoni R; Chang AA; Saffar I; Gedif K; Wong DT
Journal
British Journal of Ophthalmology, Vol. 108, No. 6, pp. 852–858
Publisher
BMJ
Publication Date
6 2024
DOI
10.1136/bjo-2023-323577
ISSN
0007-1161
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
HumansReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsTomography, Optical CoherenceVisual AcuityAngiogenesis InhibitorsIntravitreal InjectionsWet Macular DegenerationMaleFemaleAntibodies, Monoclonal, HumanizedAgedVascular Endothelial Growth Factor ADouble-Blind MethodRetinaTreatment Outcome